Literature DB >> 34622350

Use of antibiotics and factors associated with treatment failure among 152,245 patients with pneumonia treated in the community - a retrospective cohort study.

A Reiner-Benaim1, A Neuberger2,3, G Chodick4, Oryan Henig5.   

Abstract

This study aims to evaluate risk factors associated with treatment failure and the antibiotics prescribed by primary care physicians in a large patient cohort treated for pneumonia in the community. A retrospective cohort study based on the databases of Maccabi Healthcare Services that provide healthcare to a quarter of the Israeli population. Included patients were > 12 years and diagnosed with pneumonia in the outpatient setting. Cohort 1 included patients with community-acquired pneumonia (CAP), whereas cohort 2 included patients with a documented pneumonia diagnosis following hospital discharge. Treatment failure (TF) was defined as either the use of a second line antibiotic OR hospital admission within 3-14 days OR death within 30 days of diagnosis. Risk factors for TF in the study cohorts were analyzed using multivariable logistic regression. During the study period, 148,376 patients were included in cohort 1 and 3,869 patients in cohort 2, with mean ages of 46.5 ± 20.3 and 63.8 ± 19.5 years, respectively. The most commonly used antibiotics were cephalosporins (36%) and macrolides (35.5%). TF occurred in 12% of cohort 1 and was associated with older age, comorbid conditions, use of non-respiratory fluoroquinolones, and penicillin. Atypical coverage (either macrolides or tetracyclines) was associated with a lower risk of failure. Among cohort 2, TF was higher (16.4%, p < 0.001) and was associated with older age, prior cancer, and congestive heart failure. Treatment failure was associated with comorbid conditions and increasing age. Among young patients with CAP and no comorbid conditions, macrolides or tetracyclines may suffice.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antibiotics; Community-acquired pneumonia; Failure; Risk factors; Treatment

Mesh:

Substances:

Year:  2021        PMID: 34622350     DOI: 10.1007/s10096-021-04357-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

Review 1.  Treatment failure in community-acquired pneumonia.

Authors:  Rosario Menendez; Antoni Torres
Journal:  Chest       Date:  2007-10       Impact factor: 9.410

2.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

3.  Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis.

Authors:  S R Ott; B M Hauptmeier; C Ernen; P M Lepper; E Nüesch; M W Pletz; J Hecht; T Welte; T T Bauer
Journal:  Eur Respir J       Date:  2011-09-29       Impact factor: 16.671

4.  Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

Authors:  R Menéndez; A Torres; R Zalacaín; J Aspa; J J Martín Villasclaras; L Borderías; J M Benítez Moya; J Ruiz-Manzano; F Rodríguez de Castro; J Blanquer; D Pérez; C Puzo; F Sánchez Gascón; J Gallardo; C Alvarez; L Molinos
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

Review 5.  Atypical pathogens and challenges in community-acquired pneumonia.

Authors:  Kristopher P Thibodeau; Anthony J Viera
Journal:  Am Fam Physician       Date:  2004-04-01       Impact factor: 3.292

Review 6.  Early and late treatment failure in community-acquired pneumonia.

Authors:  Carolina Garcia-Vidal; Jordi Carratalà
Journal:  Semin Respir Crit Care Med       Date:  2009-03-18       Impact factor: 3.119

7.  Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.

Authors:  Xin Ye; Vanja Sikirica; Jeffrey R Schein; Richard Grant; Victoria Zarotsky; Dilesh Doshi; Carmela Janagap Benson; Aylin A Riedel
Journal:  Clin Ther       Date:  2008-02       Impact factor: 3.393

8.  Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia.

Authors:  Beatriz Rosón; Jordi Carratalà; Núria Fernández-Sabé; Fe Tubau; Frederic Manresa; Francesc Gudiol
Journal:  Arch Intern Med       Date:  2004-03-08

9.  A nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7.

Authors:  Gili Regev-Yochay; Galia Rahav; Jacob Strahilevitz; Jihad Bishara; Michal Katzir; Michal Chowers; Renato Finkelstein; Bibiana Chazan; Oren Zimhony; Ron Dagan
Journal:  Vaccine       Date:  2013-03-19       Impact factor: 3.641

10.  Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study.

Authors:  Glenn Tillotson; Thomas Lodise; Peter Classi; Donna Mildvan; James A McKinnell
Journal:  Open Forum Infect Dis       Date:  2020-02-26       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.